Lcrv | List of Frontiers open access articles

Original Research

Published on 02 Aug 2019

Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model

in Vaccines and Molecular Therapeutics

Catherine Daniel
Amélie Dewitte
Sabine Poiret
Michaël Marceau
Michel Simonet
Laure Marceau
Guillaume Descombes
Denise Boutillier
Nadia Bennaceur
Sébastien Bontemps-Gallo

Frontiers in Immunology

doi 10.3389/fimmu.2019.01830

5,072 views
25 citations

Original Research

Published on 05 Dec 2016

The Amino-Terminal Part of the Needle-Tip Translocator LcrV of Yersinia pseudotuberculosis Is Required for Early Targeting of YopH and In vivo Virulence

in Bacteria and Host

Sofie Ekestubbe
Jeanette E. Bröms
Tomas Edgren
Maria Fällman
Matthew S. Francis
Åke Forsberg

Frontiers in Cellular and Infection Microbiology

doi 10.3389/fcimb.2016.00175

5,762 views
7 citations

Original Research

Published on 12 Jun 2020

Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis

in Vaccines and Molecular Therapeutics

Ankit Gupta
Bineet Narayan
Subodh Kumar
Shailendra Kumar Verma

Frontiers in Immunology

doi 10.3389/fimmu.2020.00988

7,741 views
12 citations

Review

Published on 06 Feb 2013

Regulation of the Yersinia type III secretion system: traffic control

in Bacteria and Host

Rebecca Dewoody
Peter M. Merritt
Melanie M. Marketon

Frontiers in Cellular and Infection Microbiology

doi 10.3389/fcimb.2013.00004

25,255 views
108 citations

Original Research

Published on 16 Dec 2015

Recombinant Bivalent Fusion Protein rVE Induces CD4+ and CD8+ T-Cell Mediated Memory Immune Response for Protection Against Yersinia enterocolitica Infection

in Microbial Immunology

Amit K. Singh
Joseph J. Kingston
Shishir K. Gupta
Harsh V. Batra

Frontiers in Microbiology

doi 10.3389/fmicb.2015.01407

4,594 views
7 citations

Original Research

Published on 26 Jun 2025

Nanolipoprotein particle (NLP) vaccine confers protection against Yersinia pestis aerosol challenge in a BALB/c mouse model

in Vaccines and Molecular Therapeutics

Sergei S. Biryukov
Amy Rasley
Michael L. Davies
Christopher P. Klimko
Jennifer L. Dankmeyer
Melissa Hunter
Nathaniel O. Rill
Jennifer L. Shoe
Jeremy Miller
Yuli Talyansky

Frontiers in Immunology

doi 10.3389/fimmu.2025.1603710

3,825 views

Original Research

Published on 05 Jul 2016

A Recombinant Trivalent Fusion Protein F1–LcrV–HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis

in Microbial Immunology

Shailendra K. Verma
Lalit Batra
Urmil Tuteja

Frontiers in Microbiology

doi 10.3389/fmicb.2016.01053

5,754 views
12 citations

Articles

Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model

The Amino-Terminal Part of the Needle-Tip Translocator LcrV of Yersinia pseudotuberculosis Is Required for Early Targeting of YopH and In vivo Virulence

Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis

Regulation of the Yersinia type III secretion system: traffic control

Recombinant Bivalent Fusion Protein rVE Induces CD4+ and CD8+ T-Cell Mediated Memory Immune Response for Protection Against Yersinia enterocolitica Infection

Nanolipoprotein particle (NLP) vaccine confers protection against Yersinia pestis aerosol challenge in a BALB/c mouse model

A Recombinant Trivalent Fusion Protein F1–LcrV–HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis